Minireviews
Copyright ©The Author(s) 2021.
World J Clin Oncol. Sep 24, 2021; 12(9): 787-799
Published online Sep 24, 2021. doi: 10.5306/wjco.v12.i9.787
Table 1 Real-world studies of gemcitabine/nab-paclitaxel in the first-line setting[19-23]
Ref.LocationStudy design Stage M1 nRegimenmOS in moSubgroup analysismPFS in mo Remarks
Prager et al[19], 2021 AustriaProspective cohort100%317GnP10.6/10.2Age < 70/> 705.6/5.5No difference in frequent toxicities
Blomstrand et al[20,21], 2019/2020SwedenRetrospective cohort71%75GnP10.9Alb <3 7, age < 65 with shorter survival5.2Less hematotoxicity than MPACT
Ostwal et al[22], 2018IndiaRetrospective cohort83%78GnP11.65.6Grade III-IV toxicity 35%
Quinton et al[23], 2018United KingdomRetrospective cohort100%748.4-Hematotoxicity similar to MPACT
Table 2 Real-world studies of Folfirinox in the first-line setting[24]
Ref.LocationStudy design nM1RegimenmOS in momPFS in mo Remarks
Cavanna et al[24], 2019ItalyRetrospective cohort5074%FFX/mFFX10.15.6mFFX sign less toxicity
Table 3 Real-world studies comparing Folfirinox and Gemcitabine/Nab-paclitaxel in the first-line setting[25-32]
Ref.LocationStudy design nM1 RegimenmOS in mo, P valuePrognostic factorsmPFS in mo, P valueRemarks
Franco et al[25], 2020 SpainRetrospective cohort11950%FFX 59; GnP 60FFX 12.7; GnP 10.2; P = 0.912Ca19-9, NLR-Toxicity data not reported
Wang et al[26], 2019CanadaRetrospective cohort22558%FFX 92; GnP 87; Gem 46FFX 14.1; GnP 10.5; Gem 4.2-FFX 8.4; GnP 8.5; Gem 3.7Sign more hematotoxicity in FFX
Pusceddu et al[27], 2019-Review3813NAFFX 1690; GnP 21231.15 longer for FFX. P = 0.03--GnP more neurotoxicity and anemia. FFX more neutropenia
Chiorean et al[28], 2019-Review> 6915NAFFX > 3556; GnP > 3359FFX 15.9; GnP 14.4-FFX 11.7; GnP 8.5FFX more neutropenia, GnP more neuropathy
Papneja et al[29], 2019CanadaRetrospective cohort11977%FFX 86; GnP 33FFX 9.0; GnP 9.0S-Alb, male sex, 2nd line therapyFFX 6.0; GnP 4.0 Grade 1-2 thromboembolism, mucositis and neuropathy sign more in FFX. Among grade 3-4 toxicity only fatigue sign more in GnP group
Kordes et al[32], 2019SwedenRetrospective cohort595-FFX 31; GnP 66; Gem 185FFX 9.9; GnP 9.8; Gem 6.6--No sign differences in toxicity comparing FFX vs GnP
Cartwright et al[30], 2018United StatesRetrospective cohort486100%FFX 159; GnP 255; Gem 72FFX 11.4; GnP 9.8; Gem 4.4--No sign differences in toxicity comparing FFX vs GnP
Kim et al[31], 2018United StatesRetrospective cohort654100%FFX 317; GnP 337FFX 13.8; GnP 12.1; P = 0.96Age-Less toxicity in GnP group
Table 4 Real-world studies of second-line therapy following failure of Folfirinox[36-44]
Ref.nM12L regimenmPFS in momOS in moRemarksAE
Portal et al[36], 201557100%GnP5.18.8Prospective cohort38% grade 3-4 toxicity
Mita et al[37], 20193080%GnP3.87.6Phase II70% grade 3-4 toxicity
Tsang et al[38], 201915967%GnP 78; Gem 81-5.8; 4.6Population-based, three Canadian provinces-
Zhang et al[39], 20186073%; 75%; 73%GnP 30; Gem 8; BSC 223.6; 2.55.7; 3.8Single centerMore grade 3-4 fatigue in Gem
Nguyen et al[40], 20173077%GnP3.712.4Single centerGrade 3-4 thrombocytopenia (33%), anemia (23%), nausea (17%)
Bertocchi et al[41], 201523100%GnP3.05.0Single center-
Zhang et al[42], 20152882%GnP3.0 5.7Single centerGrade 3-4, anemia (25%), thrombocytopenia (25%), neutropenia (18%)
Caparello et al[44], 201671-GnP2.56.2Single center-
Rissy et al[43], 201712100%GnP4.9-Single-centerNo grade 3-4 toxicity reported
Table 5 Real-world studies of second-line treatment with Folfirinox following failure of gemcitabine/nab-paclitaxel or single-agent gemcitabine[46-51]
Ref.nM11L regimen2L regimenmPFS in momOS in moRemarks
Sawada et al[46], 2020104100%GnPModified; FFX3.97.0Bolus 5-FU omitted. 55% grade 3-4 toxicity
Matsumoto et al[47], 20202383%GnPFFX 12; mFFX 115.3; 4.36.9; 12.8No sign difference in toxicity between FFX/mFFX
Assaf et al[50], 201127100%GemFFX3.08.556% grade 3-4 neutropenia
Kobayashi et al[48], 201718100%GemFFX2.89.8Phase I/II. 83% grade 3-4 toxicity
Kim et al[51], 20183982%GemAttenuated; FFX3.88.5Oxaliplatin: 65 mg/m2. 41% grade 3-4 neutropenia
Chung et al[49], 20184879%GemReduced irinotecan and oxaliplatin; FFX5.89.0Phase IIIrinotecan: 120 mg/m2; Oxaliplatin: 60 mg/m2; 65% grade 3-4 neutropenia